COVIDRIVE is a not-for-profit public-private partnership launched in June 2021 to address the joint need to monitor COVID-19 vaccination programs for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. The first COVID-19 vaccine effectiveness study started in September 2021. P95 co-coordinates the vaccine effectiveness studies as one of the non-industry partners.

Read more about COVIDRIVE on the project website: https://covidrive.eu/